Abbott to Separate Nutrition Unit, Lowers 2026 Sales Growth Outlook
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
Abbott (ABT) stock fell 8% after missing Q4 earnings expectations, with nutrition sales dropping 8.9% due to lower volumes and strategic price cuts on baby formula and supplements.